Med. praxi. 2024;21(3):177-182

Kam kráčí kardiovaskulární prevence aneb jak žít déle

MUDr. Zuzana Zafarová

Zpracováno na základě přednášky MUDr. Jaromíra Ožany


Diabetologická, endokrinologická a kardiologická ambulance Zábřeh

Klinika tělovýchovného lékařství a kardiovaskulární rehabilitace FN Olomouc

Published: June 17, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zafarová Z. Kam kráčí kardiovaskulární prevence aneb jak žít déle. Med. praxi. 2024;21(3):177-182.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-188. doi:10.1093/eurheartj/ehz455. Go to original source... Go to PubMed...
    2. Vráblík M, Piťha J, Blaha V, et al. Stanovisko výboru České společnosti pro aterosklerózu k doporučením ESC/EAS pro diagnostiku a léčbu dyslipidemií z roku 2019. Hypertenze a KV prevence 2019;2:68-77. Go to original source...
    3. Čilíková K. Čas, klíčový hráč v redukci srdečněcévního rizika. Medical Tribune 25/2019. Available from: https://www.tribune.cz/archiv/cas­‑klicovy­‑hrac­‑v-redukci­‑srdecnecevniho­‑rizika/.
    4. Ference BA, Bhatt DL, Catapano AL, et al. Association of Genetic Variants Related to Combined Exposure to Lower Low­‑Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. JAMA. 2019 Oct 8;322(14):1381-1391. doi: 10.1001/jama.2019.14120. PMID: 31475726; PMCID: PMC6724415. Go to original source... Go to PubMed...
    5. Burger PM, Dorresteijn JAN, Koudstaal S, et al. Course of the effects of LDL­‑cholesterol reduction on cardiovascular risk over time: a meta­‑analysis of 59 trials. Eur heart J 2023;44(Suppl 2):ehad655.2515. Go to original source...
    6. Olsen MH, Angell SY, Asma S, et al. A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. Lancet. 2016 Nov 26; 388(10060):2665-2712. Go to original source... Go to PubMed...
    7. Cuende JI, Cuende N, Calaveras­‑Lagartos J. How to calculate vascular age with the SCORE project scales: a new method of cardiovascular risk evaluation. Eur Heart J. 2010 Oct;31(19):2351-2358. Go to original source... Go to PubMed...
    8. Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023 Dec 1;41(12):1874-2071. Go to original source... Go to PubMed...
    9. Sever PS, Dahlöf B, Poulter NR, et al; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower­‑than­‑average cholesterol concentrations, in the Anglo­‑Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT­‑LLA): a multicentre randomised controlled trial. Lancet. 2003 Apr 5;361(9364):1149-1158. Go to original source... Go to PubMed...
    10. Sever P, Dahlöf B, Poulter N, et al; ASCOT Steering Committee Members. Potential synergy between lipid­‑lowering and blood­‑pressure­‑lowering in the Anglo­‑Scandinavian Cardiac Outcomes Trial. Eur Heart J. 2006 Dec;27(24):2982-2988. Go to original source... Go to PubMed...
    11. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid­‑lowering therapy. Arch Intern Med. 2005 May 23;165(10):1147-1152. Go to original source... Go to PubMed...
    12. Gupta P, Patel P, Štrauch B, et al. Biochemical Screening for Nonadherence Is Associated With Blood Pressure Reduction and Improvement in Adherence. Hypertension. 2017 Nov;70(5):1042-1048. Go to original source... Go to PubMed...
    13. Castellano JM, Sanz G, Fernandez Ortiz A, et al. A polypill strategy to improve global secondary cardiovascular prevention: from concept to reality. J Am Coll Cardiol. 2014 Aug 12;64(6):613-621. Go to original source... Go to PubMed...
    14. Selak V, Elley CR, Bullen C, et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ. 2014 May 27;348:g3318. Go to original source... Go to PubMed...
    15. Thom S, Poulter N, Field J, et al; UMPIRE Collaborative Group. Effects of a fixed­‑dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA. 2013 Sep 4;310(9):918-929. Go to original source... Go to PubMed...
    16. Huffman MD. The Polypill: From Promise to Pragmatism. PLoS Med. 2015 Aug 11;12(8):e1001862. Go to original source... Go to PubMed...
    17. Castellano JM, Pocock SJ, Bhatt DL, et al; SECURE Investigators. Polypill Strategy in Secondary Cardiovascular Prevention. N Engl J Med. 2022 Sep 15;387(11):967-977. Go to original source... Go to PubMed...
    18. Cicero AFG, Fogacci F, Rizzoli E, et al; Brisighella Heart Study Group. Impact of simultaneous management of hypertension and hypercholesterolemia with ACE inhibitors and statins on cardiovascular outcomes in the Brisighella Heart Study: A 8-year follow­‑up. Nutr Metab Cardiovasc, DiS. 2022 Sep;32(9):2246-2254. doi: 10.1016/j.numecd.2022. 06. 017. Epub 2022 Jun 30. PMID: 35843791. Go to original source...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.